KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Return on Equity (2016 - 2025)

Regeneron Pharmaceuticals has reported Return on Equity over the past 16 years, most recently at 0.14% for Q4 2025.

  • Quarterly results put Return on Equity at 0.14% for Q4 2025, down 1.0% from a year ago — trailing twelve months through Dec 2025 was 0.14% (down 1.0% YoY), and the annual figure for FY2025 was 0.15%, down 1.0%.
  • Return on Equity for Q4 2025 was 0.14% at Regeneron Pharmaceuticals, down from 0.15% in the prior quarter.
  • Over the last five years, Return on Equity for REGN hit a ceiling of 0.46% in Q2 2021 and a floor of 0.14% in Q4 2025.
  • Median Return on Equity over the past 5 years was 0.17% (2023), compared with a mean of 0.24%.
  • Biggest five-year swings in Return on Equity: grew 18bps in 2021 and later fell -25bps in 2022.
  • Regeneron Pharmaceuticals' Return on Equity stood at 0.45% in 2021, then plummeted by -56bps to 0.2% in 2022, then fell by -21bps to 0.16% in 2023, then fell by -3bps to 0.15% in 2024, then dropped by -4bps to 0.14% in 2025.
  • The last three reported values for Return on Equity were 0.14% (Q4 2025), 0.15% (Q3 2025), and 0.15% (Q2 2025) per Business Quant data.